CA AB432

Requires health care service plans and health insurance policies covering outpatient prescription drugs (issued, amended, or renewed on or after January 1, 2026) to cover evaluation and treatment options for perimenopause and menopause symptoms without utilization management, including at least one drug in each formulation for systemic hormone therapy, nonhormonal medications, genitourinary syndrome treatments, and osteoporosis medications

Provides double continuing education credit (2 hours for each hour completed, up to 8 hours total) for qualifying physicians and surgeons who complete coursework on perimenopause, menopause, and postmenopausal care from July 1, 2026 until July 1, 2032

Qualifying physicians include board-certified internists, family physicians, OB-GYNs, cardiologists, endocrinologists, neurologists, and psychiatrists whose patient population is at least 25% adult women under 65

Requires health plans and insurers to annually provide clinical care recommendations for hormone therapy from the Menopause Society or other nationally recognized professional associations to contracted primary care providers treating patients with perimenopause and menopause

Coverage must be provided without discrimination based on gender expression or identity, and does not apply to Medi-Cal managed care plans or specialized health care service plan contracts